Imaging Biomarkers in Preclinical and Symptomatic AD. (ACS PiB IND)
Who is this study for? Adult patients with Alzheimer's Disease
What treatments are being studied? 11C Pittsburgh Compound B
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The purpose of this research study is to evaluate adult children of parents with and without Alzheimer's disease which represent an ideal population for investigating the biological changes that precede the clinical onset of AD. The investigators will be imaging the brain to detect the presence of amyloid deposits (plaques in the brain). Amyloid is a protein that may be related to dementia of Alzheimer's disease (DAT).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Male or female, any race;
• Age ≥ 18 years;
• Active participants currently enrolled in the Knight Alzheimer's Disease Research Center (ADRC) at Washington University.
Locations
United States
Missouri
Washington University School of Medicine
RECRUITING
St Louis
Contact Information
Primary
Kelley Jackson
kelleyj@wustl.edu
314-297-7602
Time Frame
Start Date: 2021-06-08
Estimated Completion Date: 2029-10
Participants
Target number of participants: 375
Treatments
[11C] Pittsburgh Compound-B (PIB)
Using \[11C\] Pittsburgh Compound-B (PIB) to look for biomarkers in preclinical and symptomatic AD.
Related Therapeutic Areas
Sponsors
Leads: Tammie L. S. Benzinger, MD, PhD